Q-omics provides the consensus-scored ANAPC10 profile across patient tissues and cancer cell-line models. ANAPC10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ANAPC10 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ANAPC10 RNA expression shows 20,504 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where ANAPC10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANAPC10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANAPC10 survival associations across molecular data types. ANAPC10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANAPC10 RNA expression–survival associations across cancer types. High ANAPC10 expression shows unfavorable associations in HNSC, UVM, LIHC, LGG and KICH, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for ANAPC10 RNA expression.
This table summarizes ANAPC10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ANAPC10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANAPC10 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, STAD and COAD. The HNSC box plot shows higher ANAPC10 RNA expression in tumor versus normal tissue (log2 FC = +0.680, t-test p < 0.001).
This table shows molecular features associated with ANAPC10 in patient tissues and cancer cell lines. In patient samples, ANAPC10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANAPC10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
